Hannah Brendan
SEC insider (Form 3/4/5 filer). CIK 0001929422. CBO, COO & CCO at Quince Therapeutics, Inc. (QNCX). 5 reported Form 4/5 transactions since Sep 2024; latest on Jan 23, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Hannah Brendan has filed insider reports for
- Quince Therapeutics, Inc. (QNCX): Officer, CBO, COO & CCO
Hannah Brendan
CIK: 0001929422
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Quince Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jan 23, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
365K shares- - Dec 5, 2025QNCX
Quince Therapeutics, Inc.
ExerciseDirect2.3K shares at avg. $0.55$1K - Dec 5, 2025QNCX
Quince Therapeutics, Inc.
ExerciseDirect25.3K shares at avg. $0.94$24K - Jun 18, 2025QNCX
Quince Therapeutics, Inc.
AwardDirect37.7K shares at avg. $1.20$45K - Jan 28, 2025QNCX
Quince Therapeutics, Inc.
AwardDirectEmployee Stock Option (right to buy)
450K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 23, 2026 | QNCX Quince Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 365,000 | - | - | Direct |
| Dec 5, 2025 | QNCX Quince Therapeutics, Inc. | Exercise | 2,271 | $0.55 | $1,249 | Direct |
| Dec 5, 2025 | QNCX Quince Therapeutics, Inc. | Exercise | 25,280 | $0.94 | $23,763 | Direct |
| Jun 18, 2025 | QNCX Quince Therapeutics, Inc. | Award | 37,736 | $1.20 | $45,283 | Direct |
| Jan 28, 2025 | QNCX Quince Therapeutics, Inc. | Award Employee Stock Option (right to buy) | 450,000 | - | - | Direct |
1-5 of 5 transactions